Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a drug called Corabotase IPN10200 compared to a placebo for treating adults with Cervical Dystonia CD. CD causes abnormal movements and symptoms in the head and neck, such as neck pain, stiffness, and headaches. The condition may involve brain regions that control movement and could be influenced by genetic and environmental factors. This study is a Phase II trial aiming to find out if Corabotase can provide longer-lasting relief than current treatments. Participants will receive a single intramuscular injection of either Corabotase at one of three doses Dose A, Dose B, or Dose C or a placebo on Day 1 of the treatment period. The injections target muscles in the head, neck, and shoulders. The study includes two periods a Screening Period lasting up to 4 weeks to determine eligibility, followed by a 36-week Treatment Period. Participants may continue some other medications during the study, which will be recorded. During the study, participants will attend 10 in-person clinic visits and one remote visit phone call, or 12 in-person visits if receiving Dose C. They will undergo blood and urine tests, physical and neurological exams, and clinical evaluations. Participants will also fill out questionnaires throughout the study. The main outcome measured is the change in severity of CD symptoms using a specific rating scale at Week 4. Total participation lasts about 40 weeks approximately 9 months.
Actively Recruiting
Acute ischemic stroke AIS is a serious condition caused by a sudden blockage of blood flow to part of the brain due to a clot forming in or traveling to brain vessels. This trial evaluates TAK-755, a study drug, to assess its safety and how well adults with AIS tolerate it. The study also examines whether TAK-755 can help improve participants daily functioning and reduce stroke symptom severity compared to a placebo, which looks like the drug but contains no medicine. Participants will receive a single intravenous infusion of either TAK-755 or a matching placebo on Day 1. This study includes two parts, Part A and Part B, with participants randomly assigned to receive TAK-755 or placebo in either part. After the infusion, all participants will continue to receive standard stroke care as per hospital practice, with health monitored for up to 90 days. Throughout the study, participants will be followed for about three months to monitor their health, including checking for any bleeding complications within 120 hours after treatment. Researchers will assess stroke severity, recovery, and brain imaging outcomes at multiple time points, including 24 hours, 72 hours, and 90 days. Safety evaluations will include monitoring adverse events, vital signs, blood tests, and antibody responses. The goal is to gather detailed information on how TAK-755 affects stroke recovery and participant safety over this period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of whole-body hypothermia for newborn babies with mild hypoxic ischaemic encephalopathy. This phase III randomised controlled trial aims to determine whether cooling the whole body to 33.5.5C within six hours after birth and continuing for 72 hours improves cognitive development at around two years of age compared with maintaining normal body temperature. The study also seeks to assess the economic value of cooling therapy for mild encephalopathy within the healthcare system. Babies born at or after 36 weeks with signs of birth asphyxia or acidosis will be randomly assigned to receive either whole-body hypothermia or targeted normothermia. Cooling will be applied using a servo-controlled machine in neonatal intensive care units, maintaining a rectal temperature of about 33.5C for 72 hours. The control group will have their body temperature kept at normal levels 37C for the first 80 hours, with any fever carefully treated. Babies born at non-cooling centers will be transferred to specialized units for treatment. During the study, participants will undergo brain monitoring, MRI scans before discharge, and follow-up developmental assessments at 24 months using the Bayley Scales of Infant and Toddler Development IV. Additional evaluations will include neurological exams, motor function assessments, vision and hearing tests, and parent-completed questionnaires. Researchers will collect detailed clinical data from birth through hospital stay, aiming to compare cognitive outcomes and safety measures between the two groups over the study period.
Actively Recruiting
Researchers are evaluating surgical options for patients with low risk differentiated thyroid cancer. This phase III study aims to determine if hemithyroidectomy, which removes part of the thyroid gland, is an acceptable and cost-effective alternative to total thyroidectomy, which removes the entire gland. The trial includes two groups of patients based on their prior surgery status and diagnosis method, focusing on recurrence risk and prognosis. Participants are randomly assigned to different surgical treatments depending on their group. Group 1 patients who have had prior thyroid surgery will either have a second operation to remove the remaining thyroid tissue or undergo surveillance without further surgery. Group 2 patients who have not had surgery will be randomized to receive either hemithyroidectomy or total thyroidectomy in a single operation. The trial plans to recruit 456 participants and follow them regularly for six years after surgery. During the study, patients will attend follow-up visits post-surgery and then annually for six years. Researchers will monitor cancer recurrence rates at three and five years, assess the site and risk of recurrence, and record additional investigations and procedures after surgery. They will also evaluate surgical complications, voice function, hormone replacement needs, quality of life, and healthcare resource use at multiple time points. This comprehensive monitoring aims to compare outcomes between the different surgical approaches and understand their impact on patients health and well-being over time.
Actively Recruiting
Researchers are evaluating the benefits and risks of an intensive weight loss intervention compared to bariatric surgery in adults with severe and complex obesity. The goal is to inform future care options for people for whom bariatric surgery is currently the only effective treatment. This randomized trial is led by Carsten Dirksen and aims to compare these approaches over a two-year period. The intensive weight loss intervention includes three phases over two years an induction phase with total dietary replacements and behavioral support possibly combined with weight loss medication, a weight loss continuation phase involving gradual reintroduction of healthy foods, physical activity, and medication as needed, and a maintenance phase focusing on sustained healthy diet and activity with medication if required. The surgery group will receive either Roux-en-Y gastric bypass or sleeve gastrectomy. Participants will be closely followed for two years after randomization with assessments including metabolic syndrome measures, body weight, walking speed, and mental health status. The study uses double-blind randomization and includes regular behavioral support and monitoring. The results will help understand which treatment offers better outcomes for adults aged 18 to 60 with severe obesity and related health conditions.
Actively Recruiting
This research aims to investigate how often complications occur after bariatric surgery in patients across the United Kingdom and how these complications are managed. It seeks to understand the prevalence of unplanned interventions, current management practices, and their effects on patient outcomes. By examining these factors, the study hopes to identify the best ways to provide emergency bariatric care and understand influences such as patient demographics and previous engagement with NHS weight management services. Participants will be identified when they present at hospitals with complications following bariatric surgery. Data will be collected on their demographics, surgical history, the type and site of their bariatric surgery, complications, treatments, and outcomes. This observational study will gather information through electronic health records and manual extraction over a six-month period at each center, without assigning any treatments or interventions. During the study, researchers will analyze patient information to compare different treatment approaches and their impact on outcomes like 30-day mortality, length of hospital stay, and complication severity. They will also track secondary outcomes such as nutritional support use, surgeries or procedures performed, critical care admissions, and engagement with specialized weight management services. Data quality will be ensured through checks, and missing information will be requested from participating centers. Overall, the study will provide insights over about a year on these key outcomes following bariatric surgery complications.
Actively Recruiting
Researchers are investigating the prevalence and severity of Periodontal Disease PD in adults with obesity who are receiving bariatric care. The study also aims to explore inflammatory biomarkers linked to PD in saliva, examine the association of FTO gene polymorphisms with PD prevalence, and analyze the subgingival microbial flora in this population. This is a cross-sectional observational study conducted at a bariatric clinic. Participants will undergo routine care including medical examination with recording of various parameters such as age, gender, smoking status, body composition, ethnicity, and body mass index. Blood samples will be taken for genetic analysis if DNA samples are not already available. All participants will receive a basic periodontal examination, and if signs of destructive periodontitis are detected, more detailed periodontal assessments and microbial sampling will be performed. During the single study visit, participants will have periodontal evaluations, saliva and subgingival plaque samples collected, and possibly blood samples taken. These assessments will take up to two hours from consent. Researchers will measure the prevalence of PD, inflammatory biomarkers in saliva, genetic polymorphisms, and microbial flora. There is no additional follow-up, and the study duration for each participant is limited to this single visit.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
1-10 of 16
1